Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Open accessThe DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growth factor intravitreal injection methods. However, because intravitreal treatment requires monthly or bimonthly repeat injections to achieve optimal efficacy, recent investigations have focused on extended drug delivery systems to lengthen the treatment intervals in the long term. Dose escalation and increasing molecular weight of drugs, intravitreal implants and nanoparticles, hydrogels, combined systems, and port delivery systems are presently under preclinical and clinical investigations. In addition, less invasive techniques rather than intravitreal administration routes, such as topical, subconjunctival, suprachoroidal, subretinal, and trans-scleral, have been evaluated to reduce the treatment burden. Despite the latest advancements in the field of ophthalmic pharmacology, enhancing drug efficacy with high ocular bioavailability while avoiding systemic and local adverse effects is quite challenging. Consequently, despite the performance of numerous in vitro studies, only a few techniques have translated to clinical trials. This review discusses the recent developments in ocular drug delivery to the retina, the pharmacokinetics of intravitreal drugs, efforts to extend drug efficacy in the intraocular space, minimally invasive techniques for drug delivery to the retina, and future perspectives in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Biodegradable and non-biodegradable ocular implants have been used in several drug treatments for conditions such as diabetic macular edema and posterior uveitis, among others, and provide a method for sustained release of poorly soluble steroids.118,126”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [126]
Experimental — accuracy not yet measuredIn the citing paper
“In the field of ophthalmology, different routes of administration, such as subconjunctival, intravitreal, suprachoroidal and subretinal injections, are commonly used to treat various diseases61.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Hyaluronic Acid Hydrogels for Biomedical Applications
Burdick, J. A., & Prestwich, G. D. (2011) · Advanced Materials · doi:10.1002/adma.201003963 · Cited by 2,139
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
Polymer nanoparticles: Preparation techniques and size-control parameters
Rao, J. P., & Geckeler, K. E. (2011) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.01.001 · Cited by 1,725
Dendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., Rubio, R. G., & Murahashi, W. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.022 · Cited by 1,155
Hydrogels for Protein Delivery
Vermonden, T., Censi, R., & Hennink, W. E. (2012) · Chemical Reviews · doi:10.1021/cr200157d · Cited by 1,091
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931 · cited 14×
“Currently, randomized, double-masked, phase 3 clinical trials are being conducted with high-dose aflibercept every 12 or 16 weeks after a loading phase in participants with diabetic retinopathy (PHOTON; NCT04429503) and neovascular AMD (PULSAR; NCT04423718).”
BackgroundInfluentialOcular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Campochiaro, P. A., Brown, D. M., Awh, C. C., Lee, S. Y., Gray, S., Saroj, N., Murahashi, W. Y., & Rubio, R. G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.038 · Cited by 711
Ophthalmic drug delivery systems—Recent advances
Le Bourlais, C., Acar, L., Zia, H., Sado, P. A., Needham, T., & Leverge, R. (1998) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(97)00002-5 · Cited by 698
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 615
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 605
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
Beer, P. M., Bakri, S. J., Singh, R. J., Liu, W., Peters, G. B., & Miller, M. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01969-3 · Cited by 570
Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., Ezzat, M. K., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.012 · Cited by 541
Cunha-Vaz, J., Bernardes, R., & Lobo, C. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2010.6049 · Cited by 539
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Gaudreault, J., Fei, D., Rusit, J., Suboc, P., & Shiu, V. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0601 · Cited by 501
Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500
Brown, D. M., Campochiaro, P. A., Bhisitkul, R. B., Ho, A. C., Gray, S., Saroj, N., Adamis, A. P., Rubio, R. G., & Murahashi, W. Y. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.022 · Cited by 465
Kuppermann, B. D. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.3.309 · Cited by 429
Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice
BarathManiKanth, S., Kalishwaralal, K., Sriram, M., Pandian, S. R. K., Youn, H.-S., Eom, S., & Gurunathan, S. (2010) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-8-16 · Cited by 386
Regula, J. T., Lundh von Leithner, P., Foxton, R., Barathi, V. A., Cheung, C. M. G., Bo Tun, S. B., Wey, Y. S., Iwata, D., Dostalek, M., Moelleken, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505889 · Cited by 376
Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Krohne, T. U., Eter, N., Holz, F. G., & Meyer, C. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.036 · Cited by 363
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Heier, J. S., Antoszyk, A. N., Pavan, P. R., Leff, S. R., Rosenfeld, P. J., Ciulla, T. A., Dreyer, R. F., Gentile, R. C., Sy, J. P., Hantsbarger, G., et al. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.052 · Cited by 360
Varela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
YORK, A., KIRKLAND, S., & MCCORMICK, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.006 · Cited by 349
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
Baumal, C. R., Spaide, R. F., Vajzovic, L., Freund, K. B., Walter, S. D., John, V., Rich, R., Chaudhry, N., Lakhanpal, R. R., Oellers, P. R., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.017 · Cited by 312
Ocular novel drug delivery: impacts of membranes and barriers
Barar, J., Javadzadeh, A. R., & Omidi, Y. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.5.567 · Cited by 308
In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery
Al Khateb, K., Ozhmukhametova, E. K., Mussin, M. N., Seilkhanov, S. K., Rakhypbekov, T. K., Lau, W. M., & Khutoryanskiy, V. V. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.027 · Cited by 281
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Campochiaro, P. A., Marcus, D. M., Awh, C. C., Regillo, C., Adamis, A. P., Bantseev, V., Chiang, Y., Ehrlich, J. S., Erickson, S., Hanley, W. D., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.036 · Cited by 272
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269
Mehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging
Kompella, U. B., Amrite, A. C., Pacha Ravi, R., & Durazo, S. A. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.04.001 · Cited by 258
Periocular routes for retinal drug delivery
Raghava, S., Hammond, M., & Kompella, U. B. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.99 · Cited by 257
Gaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00843-z · Cited by 255 · cited 1×
“These microcrystal TA drug particles form a depot after intravitreal injection, thereby inducing controlled release and long-lasting therapeutic effects [71].”
BackgroundLong-term outcomes of treatment of neovascular age-related macular degeneration
Gillies, M. C., Campain, A., Barthelmes, D., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Essex, R. W., Morlet, N., & Hunyor, A. P. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.010 · Cited by 254
Patel, S. R., Berezovsky, D. E., McCarey, B. E., Zarnitsyn, V., Edelhauser, H. F., & Prausnitz, M. R. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9872 · Cited by 241
Kompella, U. B., Bandi, N., & Ayalasomayajula, S. P. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0791 · Cited by 239
Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Krohne, T. U., Liu, Z., Holz, F. G., & Meyer, C. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.047 · Cited by 238
Dugel, P. U., Jaffe, G. J., Sallstig, P., Warburton, J., Weichselberger, A., Wieland, M., & Singerman, L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.03.057 · Cited by 236
Ocular delivery of macromolecules
Kim, Y. C., Chiang, B., Wu, X., & Prausnitz, M. R. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.043 · Cited by 232
Hydrogel Biomaterials for Application in Ocular Drug Delivery
Lynch, C. R., Kondiah, P. P. D., Choonara, Y. E., du Toit, L. C., Ally, N., & Pillay, V. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00228 · Cited by 232
Hydrogels in ophthalmic applications
Kirchhof, S., Goepferich, A. M., & Brandl, F. P. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.016 · Cited by 229
A review on recent drug delivery systems for posterior segment of eye
Nayak, K., & Misra, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.138 · Cited by 225
Novel approaches to retinal drug delivery
Janoria, K. G., Gunda, S., Boddu, S. H., & Mitra, A. K. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.371 · Cited by 213
Drolet, D. W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., Judkins, M. B., Farmer, J. A., Wolf, J. L., Gill, S. C., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007657109012 · Cited by 206
Xu, L., Lu, T., Tuomi, L., Jumbe, N., Lu, J., Eppler, S., Kuebler, P., Damico-Beyer, L. A., & Joshi, A. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10260 · Cited by 201
Iezzi, R., Guru, B. R., Glybina, I. V., Mishra, M. K., Kennedy, A., & Kannan, R. M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.010 · Cited by 192
Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis
Yeh, S., Khurana, R. N., Shah, M., Henry, C. R., Wang, R. C., Kissner, J. M., Ciulla, T. A., & Noronha, G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.01.006 · Cited by 191
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189 · cited 1×
“Manipulation of nanoparticles with a negative charge is important in the intraocular space as the vitreous matrix is anionic due to collagen and glycosaminoglycan (hyaluronic acid and heparan sulfate) [66].”
BackgroundABRISHAMI, M., GANAVATI, S. Z., SOROUSH, D., ROUHBAKHSH, M., JAAFARI, M. R., & MALAEKEH-NIKOUEI, B. (2009) · Retina · doi:10.1097/iae.0b013e3181a2f42a · Cited by 184
Holz, F. G., Dugel, P. U., Weissgerber, G., Hamilton, R., Silva, R., Bandello, F., Larsen, M., Weichselberger, A., Wenzel, A., Schmidt, A., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.030 · Cited by 184 · cited 1×
“Small molecular weight (26 kDa), higher tissue penetration, and more condensed concentration than current anti-VEGF drugs allowed clinicians to administer fewer injections (a 12 week treatment interval) [56,57].”
BackgroundOcclusive Retinal Vasculitis Following Intravitreal Brolucizumab
Witkin, A. J., Hahn, P., Murray, T. G., Arevalo, J. F., Blinder, K. J., Choudhry, N., Emerson, G. G., Goldberg, R. A., Kim, S. J., Pearlman, J., et al. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420930863 · Cited by 183
GAUDREAULT, J., FEI, D., BEYER, J. C., RYAN, A., RANGELL, L., SHIU, V., & DAMICO, L. A. (2007) · Retina · doi:10.1097/iae.0b013e318134eecd · Cited by 181
Amphiphilic block copolymers in drug delivery: advances in formulation structure and performance
Bodratti, A. M., & Alexandridis, P. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1529756 · Cited by 180
Polymer-based carriers for ophthalmic drug delivery
Imperiale, J. C., Acosta, G. B., & Sosnik, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.031 · Cited by 175
Barrier analysis of periocular drug delivery to the posterior segment
Ranta, V.-P., Mannermaa, E., Lummepuro, K., Subrizi, A., Laukkanen, A., Antopolsky, M., Murtomäki, L., Hornof, M., & Urtti, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.028 · Cited by 173
Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171
Marano, R. J., Toth, I., Wimmer, N., Brankov, M., & Rakoczy, P. E. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302579 · Cited by 164
Iluvien ™ : a new sustained delivery technology for posterior eye disease
Kane, F. E., Burdan, J., Cutino, A., & Green, K. E. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.9.1039 · Cited by 158
New Techniques for Drug Delivery to the Posterior Eye Segment
Eljarrat‐Binstock, E., Pe’er, J., & Domb, A. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0042-9 · Cited by 158
Jaffe, G. J., McCallum, R. M., Branchaud, B., Skalak, C., Butuner, Z., & Ashton, P. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.03.013 · Cited by 158
Kim, J. H., Kim, M. H., Jo, D. H., Yu, Y. S., Lee, T. G., & Kim, J. H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.030 · Cited by 157
Advances in ocular drug delivery systems
Kang‐Mieler, J. J., Rudeen, K. M., Liu, W., & Mieler, W. F. (2020) · Eye · doi:10.1038/s41433-020-0809-0 · Cited by 155
Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye
Loftsson, Þ., & Stefánsson, E. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.04.010 · Cited by 149
Robinson, M. R., Lee, S. S., Kim, H., Kim, S., Lutz, R. J., Galbán, C. J., Bungay, P. M., Yuan, P., Wang, N. S., Kim, J., et al. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.08.007 · Cited by 142
Self-citationAdvances in ocular drug delivery: emphasis on the posterior segment
Kang-Mieler, J. J., Osswald, C. R., & Mieler, W. F. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.935338 · Cited by 142
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
Haug, S. J., Hien, D. L., Uludag, G., Ngoc, T. T. T., Lajevardi, S., Halim, M. S., Sepah, Y. J., Do, D. V., & Khanani, A. M. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100680 · Cited by 142
Ayalasomayajula, S. P., & Kompella, U. B. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.019 · Cited by 141
Niwa, Y., Kakinoki, M., Sawada, T., Wang, X., & Ohji, M. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-17279 · Cited by 139
Qiu, F., Meng, T., Chen, Q., Zhou, K., Shao, Y., Matlock, G., Ma, X., Wu, W., Du, Y., Wang, X., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01319 · Cited by 130
Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations
Budai, L., HAJDU, M., Budai, M., Gróf, P., Béni, S., Noszál, B., Klebovich, I., & Antal, I. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.013 · Cited by 128
Kim, H., Robinson, M. R., Lizak, M. J., Tansey, G., Lutz, R. J., Yuan, P., Wang, N. S., & Csaky, K. G. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0091 · Cited by 128
Self-citationRodrigues, G. A., Lutz, D., Shen, J., Yuan, X., Shen, H., Cunningham, J., & Rivers, H. M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2519-x · Cited by 124
LADAS, I. D., KARAGIANNIS, D. A., ROUVAS, A. A., KOTSOLIS, A. I., LIOTSOU, A., & VERGADOS, I. (2009) · Retina · doi:10.1097/iae.0b013e31819a5f98 · Cited by 122
Sigurdsson, H. H., Konráðsdóttir, F., Loftsson, T., & Stefánsson, E. (2007) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.2007.00885.x · Cited by 122
Varshochian, R., Riazi-Esfahani, M., Jeddi‐Tehrani, M., Mahmoudi, A.-R., Aghazadeh, S., Mahbod, M., Movassat, M., Atyabi, F., Sabzevari, A., & Dinarvand, R. (2015) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35446 · Cited by 122
Yu, Y., Lau, L. C. M., Lo, A. C.-Y., & Chau, Y. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.2.5 · Cited by 119
Rajala, A., Wang, Y., Zhu, Y., Ranjo-Bishop, M., Ma, J.-X., Mao, C., & Rajala, R. V. S. (2014) · Nano Letters · doi:10.1021/nl502275s · Cited by 117
Campochiaro, P. A., Channa, R., Berger, B. B., Heier, J. S., Brown, D. M., Fiedler, U., Hepp, J., & Stumpp, M. T. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.09.032 · Cited by 116
Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study
Campochiaro, P. A., Wykoff, C. C., Brown, D. M., Boyer, D. S., Barakat, M., Taraborelli, D., & Noronha, G. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.07.013 · Cited by 115
Subconjunctival Nanoparticle Carboplatin in the Treatment of Murine Retinoblastoma
Kang, S. J. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.185 · Cited by 113
Meyer, C. H., Krohne, T. U., & Holz, F. G. (2011) · Retina · doi:10.1097/iae.0b013e318217373c · Cited by 112
Intraocular Pharmacokinetics of Ranibizumab in Vitrectomized Versus Nonvitrectomized Eyes
Ahn, S. J., Ahn, J., Park, S., Kim, H., Hwang, D. J., Park, J. H., Park, J. Y., Chung, J. Y., Park, K. H., & Woo, S. J. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13054 · Cited by 110
Self-citationStimuli sensitive hydrogels for ophthalmic drug delivery: A review
Kushwaha, S. K. S., Rai, A., & Saxena, P. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.100036 · Cited by 108
Olsen, T. W., Feng, X., Wabner, K., Csaky, K., Pambuccian, S., & Cameron, J. D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6291 · Cited by 106
Chen, M., Li, X., Liu, J., Han, Y., & Cheng, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.021 · Cited by 105
Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina
Huang, D., Chen, Y.-S., & Rupenthal, I. D. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01029 · Cited by 104
Gan, L., Wang, J., Zhao, Y., Chen, D., Zhu, C., Liu, J., & Gan, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.035 · Cited by 103
Light-Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab
Tyagi, P., Barros, M., Stansbury, J. W., & Kompella, U. B. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300716t · Cited by 103
Hutton-Smith, L. A., Gaffney, E. A., Byrne, H. M., Maini, P. K., Schwab, D., & Mazer, N. A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00849 · Cited by 99
Apaolaza, P. S., Busch, M., Asin-Prieto, E., Peynshaert, K., Rathod, R., Remaut, K., Dünker, N., & Göpferich, A. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108151 · Cited by 99
Liu, H.-A., Liu, Y.-L., Ma, Z.-Z., Wang, J.-C., & Zhang, Q. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5891 · Cited by 97
Chen, X., Li, X., Zhou, Y., Wang, X., Zhang, Y., Fan, Y., Huang, Y., & Liu, Y. (2011) · Journal of Biomaterials Applications · doi:10.1177/0885328211406563 · Cited by 97
Misra, G. P., Singh, R. S. J., Aleman, T. S., Jacobson, S. G., Gardner, T. W., & Lowe, T. L. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.025 · Cited by 96
Vitreous Penetration of Orally Administered Valacyclovir
Huynh, T. H., Johnson, M. W., Comer, G. M., & Fish, D. N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.11.016 · Cited by 94
Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model
Park, S. J., Choi, Y., Na, Y. M., Hong, H. K., Park, J. Y., Park, K. H., Chung, J., & Woo, S. J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19204 · Cited by 94
Self-citationLiu, W., Lee, B., Mieler, W. F., & Kang‐Mieler, J. J. (2018) · Current Eye Research · doi:10.1080/02713683.2018.1533983 · Cited by 94
Hydrogels for ocular drug delivery and tissue engineering
Fathi, M., Barar, J., Aghanejad, A., & Omidi, Y. (2015) · Bioimpacts · doi:10.15171/bi.2015.31 · Cited by 93
Liposomes as an ocular delivery system of fluconazole: in‐vitro studies
HABIB, F. S., Fouad, E. A., Abdel‐Rhaman, M. S., & Fathalla, D. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01584.x · Cited by 92
Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit
Li, H., Lei, N., Zhang, M., Li, Y., Xiao, H., & Hao, X. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.09.002 · Cited by 92
Subconjunctival Carboplatin in Fibrin Sealant in the Treatment of Transgenic Murine Retinoblastoma
VANQUILL, K., Dioguardi, P. K., TONG, C., Gilbert, J. A., AABERGJR, T., Grossniklaus, H. E., EDELHAUSER, H., & OBRIEN, J. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.11.060 · Cited by 91
Tolerance of Ocular Iontophoresis in Healthy Volunteers
Parkinson, T. M., Ferguson, E. H., Febbraro, S., Bakhtyari, A., King, M., & Mundasad, M. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803321637672 · Cited by 91
Woo, S. J., Veith, M., Hamouz, J., Ernest, J., Zalewski, D., Studnička, J., Vajas, A., Papp, A., Vogt, G., Luu, J. K., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.5053 · Cited by 91
Self-citationBrown, D. M., Chen, E., Mariani, A., & Major, J. C. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.008 · Cited by 90 · cited 1×
“In the SAVE study, recalcitrant patients administered standard doses and regimens were included and injected with 2 mg doses of ranibizumab [15].”
MethodSustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles
Tsujinaka, H., Fu, J., Shen, J., Yu, Y., Hafiz, Z., Kays, J. C., McKenzie, D. A., Cardona, D., Culp, D., Peterson, W. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14340-x · Cited by 89
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
Sinapis, Sinapis, C., Σινάπης, Δ., Routsias, J. G., Pantopoulou, A., Baltatzis, S., Patsouris, E., & Perrea, D. N. (2011) · Clinical ophthalmology · doi:10.2147/opth.s19555 · Cited by 87
Biocompatible Reverse Thermal Gel Sustains the Release of Intravitreal Bevacizumab In Vivo
Rauck, B. M., Friberg, T. R., Mendez, C. A. M., Park, D., Shah, V. S., Bilonick, R. A., & Wang, Y. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13120 · Cited by 86
Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes
Ahn, J., Kim, H., Woo, S. J., Park, J. H., Park, S., Hwang, D. J., & Park, K. H. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0009 · Cited by 85
Self-citationHuang, D., Chen, Y.-S., Green, C. R., & Rupenthal, I. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.034 · Cited by 85
Kyosseva, S. V., Chen, L., Seal, S., & McGinnis, J. F. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.08.003 · Cited by 82
Takahashi, K. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.27 · Cited by 80
Kambhampati, S. P., Mishra, M. K., Mastorakos, P., Oh, Y., Lutty, G. A., & Kannan, R. M. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.013 · Cited by 78
Osswald, C. R., & Kang‐Mieler, J. J. (2016) · Current Eye Research · doi:10.3109/02713683.2015.1101140 · Cited by 75
Shatz, W., Hass, P. E., Mathieu, M., Kim, H. S., Leach, K., Zhou, M., Crawford, Y., Shen, A., Wang, K., Chang, D. P., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00345 · Cited by 73
Self-citationKang-Mieler, J. J., Dosmar, E., Liu, W., & Mieler, W. F. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1227785 · Cited by 73 · cited 1×
“Owing to the modification and fabrication of particle surfaces, compositions, polysaccharide mixtures, and ionic charges, these injected particles are distributed in the vitreous, enabling prolonged intravitreal half-lives by sustained drug release and delayed degradation and elimination [20,21].”
Human serum albumin nanoparticles for ocular delivery of bevacizumab
Luis de Redín, I., Boiero, C., Martínez-Ohárriz, M. C., Agüeros, M., Ramos, R., Peñuelas, I., Allemandi, D., Llabot, J. M., & Irache, J. M. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.02.003 · Cited by 73
Liu, W., Borrell, M. A., Venerus, D. C., Mieler, W. F., & Kang‐Mieler, J. J. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.1.12 · Cited by 73
Hutton-Smith, L. A., Gaffney, E. A., Byrne, H. M., Maini, P. K., Gadkar, K., & Mazer, N. A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00164 · Cited by 72
Kuppermann, B. D., Patel, S. S., Boyer, D. S., Augustin, A. J., Freeman, W. R., Kerr, K. J., Guo, Q., Schneider, S., López, F. J., & on behalf of the Brimo DDS Gen 1 Study Group (2020) · Retina · doi:10.1097/iae.0000000000002789 · Cited by 72
Iontophoretic transport of charged macromolecules across human sclera
Chopra, P., Hao, J., & Li, S. K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.12.046 · Cited by 71
Technical brief: subretinal injection and electroporation into adult mouse eyes.
Johnson, C. J., Berglin, L., Chrenek, M. A., Redmond, T. M., Boatright, J. H., & Nickerson, J. M. (2008) · PubMed Central · Cited by 69
Kim, H., Csaky, K. G., Gravlin, L., YUAN, P., Lutz, R. J., Bungay, P. M., Tansey, G., de Monasterio, F. M., Potti, G. K., Grimes, G. J., et al. (2006) · Retina · doi:10.1097/00006982-200605000-00005 · Cited by 69
Self-citationIn Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System
Osswald, C. R., Guthrie, M. J., Avila, A., Valio, J. A., Mieler, W. F., & Kang‐Mieler, J. J. (2017) · Current Eye Research · doi:10.1080/02713683.2017.1302590 · Cited by 69
Apaolaza, P. S., del Pozo‐Rodríguez, A., Torrecilla, J., Rodríguez‐Gascón, A., Rodríguez, J. M., Friedrich, U., Weber, B. H. F., & Solinís, M. Á. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.033 · Cited by 67
Joussen, A. M., Wolf, S., Kaiser, P. K., Boyer, D. S., Schmelter, T., Sandbrink, R., Zeitz, O., Deeg, G., Richter, A., Zimmermann, T., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13794 · Cited by 67
Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema
Wykoff, C. C., Khurana, R. N., Lampen, S. I. R., Noronha, G., Brown, D. M., Ou, W. C., & Sadda, S. R. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.03.008 · Cited by 66
Liu, J., Zhang, X., Li, G., Xu, F., Li, S., Teng, L., Li, Y., & Sun, F. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s217038 · Cited by 64
Christoforidis, J. B., Carlton, M. M., Knopp, M. V., & Hinkle, G. H. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6862 · Cited by 63
Yavuz, B., Bozdağ Pehlivan, S., Sümer Bolu, B., Nomak Sanyal, R., Vural, İ., & Ünlü, N. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12587 · Cited by 62
Giannaccini, M., Giannini, M., Calatayud, M., Goya, G., Cuschieri, A., Dente, L., & Raffa, V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15011590 · Cited by 61
Biocompatibility and Biodegradation Studies of Subconjunctival Implants in Rabbit Eyes
Peng, Y., Ang, M., Foo, S. E. M., Lee, W. S., Ma, Z., Venkatraman, S. S., & Wong, T. T. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022507 · Cited by 60
Use of rabbit eyes in pharmacokinetic studies of intraocular drugs
Ahn, S. J., Hong, H. K., Na, Y. M., Park, S. J., Ahn, J., Oh, J., Chung, J. Y., Park, K. H., & Woo, S. J. (2016) · Journal of Visualized Experiments · doi:10.3791/53878 · Cited by 60
Self-citationBhatt, P., Narvekar, P., Lalani, R., Chougule, M. B., Pathak, Y. V., & Sutariya, V. B. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1474-0 · Cited by 58
Sustained subconjunctival drug delivery systems: current trends and future perspectives
Rafiei, F., Tabesh, H., & Farzad, F. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01391-8 · Cited by 58
Doxycycline-Mediated Inhibition of Choroidal Neovascularization
Samtani, S., Amaral, J., Campos, M. M., Fariss, R. N., & Becerra, S. P. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3174 · Cited by 55
Bose, K., Kalishwaralal, K., Sheikpranbabu, S., Deepak, V., Haribalaganesh, R., & Gurunathan, S. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.09.003 · Cited by 55
Qi, Y., Dai, X., Zhang, H., He, Y., Zhang, Y., Han, J., Zhu, P., Zhang, Y., Zheng, Q., Li, X., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136523 · Cited by 54
Controlled and Extended Release of a Model Protein from a Microsphere-Hydrogel Drug Delivery System
Osswald, C. R., & Kang‐Mieler, J. J. (2015) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1314-7 · Cited by 54
Prima, G. D., Saladino, S., Bongiovì, F., Adamo, G., Ghersi, G., Pitarresi, G. L., & Giammona, G. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.05.005 · Cited by 53
Park, S. J., Oh, J., Kim, Y., Park, J.-H., Park, J. Y., Hong, H. K., Park, K. H., Lee, J.-W., Kim, H., Chung, J., et al. (2015) · Eye · doi:10.1038/eye.2014.329 · Cited by 51
Self-citationLi, C., Chen, R., Xu, M., Qiao, J., Yan, L., & Guo, X. D. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474972 · Cited by 51
Yang, X., Wang, L., Li, L., Han, M., Tang, S., Wang, T., Han, J., He, X., He, X., Wang, A., et al. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1667455 · Cited by 50
Prediction of Ocular Drug Distribution from Systemic Blood Circulation
Vellonen, K.-S., Soini, E.-M., del Amo, E. M., & Urtti, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00729 · Cited by 49
Tzameret, A., Ketter-Katz, H., Edelshtain, V., Sher, I., Corem‐Salkmon, E., Levy, I., Last, D., Guez, D., Mardor, Y., Margel, S., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0438-y · Cited by 49
Christoforidis, J. B., Briley, K. C., Binzel, K., Bhatia, P., Wei, L., Kumar, K., & Knopp, M. V. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22431 · Cited by 48
Hutton-Smith, L. A., Gaffney, E. A., Byrne, H. M., Caruso, A., Maini, P. K., & Mazer, N. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00280 · Cited by 47
Nagai, N., Kaji, H., Onami, H., Ishikawa, Y., Nishizawa, M., Osumi, N., Nakazawa, T., & Abe, T. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.11.004 · Cited by 46
Bisht, R., Jaiswal, J. K., Chen, Y.-S., Jin, J., & Rupenthal, I. D. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1163334 · Cited by 46
Magnetic nanoparticles: a strategy to target the choroidal layer in the posterior segment of the eye
Giannaccini, M., Pedicini, L., Matienzo, G. D., Chiellini, E., Dente, L., & Raffa, V. (2017) · Scientific Reports · doi:10.1038/srep43092 · Cited by 46
Intravitreal Pharmacokinetics of Liposome-encapsulated Amikacin in a Rabbit Model
Shuiqing, Z., Hu, C., Houren, W., Lu, Y., Zhang, Y., Yang, J., Yun, G., Zou, W., & Song, B. (1993) · Ophthalmology · doi:10.1016/s0161-6420(93)31423-5 · Cited by 45
Chitosan–Polycaprolactone Core–Shell Microparticles for Sustained Delivery of Bevacizumab
Jiang, P., Jacobs, K. M., Ohr, M. P., & Swindle‐Reilly, K. E. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00260 · Cited by 45
Vitreous Penetration of Orally Administered Famciclovir
Chong, D. Y., Johnson, M. W., Huynh, T. H., Hall, E. F., Comer, G. M., & Fish, D. N. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.02.010 · Cited by 45
Sustained Subconjunctival Protein Delivery Using a Thermosetting Gel Delivery System
Rieke, E. R., Amaral, J., Becerra, S. P., & Lutz, R. J. (2010) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0059 · Cited by 44
Ramazani, F., Hiemstra, C., Steendam, R., Kazazi-Hyseni, F., van Nostrum, C. F., Storm, G., Kiessling, F. M., Lammers, T., Hennink, W. E., & Kok, R. J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.011 · Cited by 42
Missel, P. J., Horner, M., & Muralikrishnan, R. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0163-1 · Cited by 42
Methylprednisolone Delivery to the Back of the Eye using Hydrogel Iontophoresis
Eljarrat‐Binstock, E., Orucov, F., Frucht‐Pery, J., Pe’er, J., & Domb, A. J. (2008) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2007.0097 · Cited by 42
Methotrexate Delivery to the Eye Using Transscleral Hydrogel Iontophoresis
Eljarrat‐Binstock, E., Domb, A. J., Orucov, F., Frucht‐Pery, J., & Pe’er, J. (2007) · Current Eye Research · doi:10.1080/02713680701528674 · Cited by 42
In vitro transscleral iontophoresis of high molecular weight neutral compounds
Nicoli, S., Ferrari, G., Quarta, M., Macaluso, C., & Santi, P. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.11.012 · Cited by 41
Guo, D. D., Li, Q. N., Li, C. M., & Bi, H. S. (2015) · Cell Proliferation · doi:10.1111/cpr.12163 · Cited by 41
Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus
Elsaid, N., Somavarapu, S., & Jackson, T. L. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.02.001 · Cited by 40
Chu, H.-S., Hu, F., Yang, C., Yeh, P., Chen, Y.-M., Hou, Y., & Chen, W. (2010) · Cornea · doi:10.1097/ico.0b013e3181e458c5 · Cited by 40
Kim, S.-H., Kang‐Mieler, J. J., Liu, W., Wang, Z., Yiu, G. C., Teixeira, L. B. C., Mieler, W. F., & Thomasy, S. M. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.30 · Cited by 39
Ye, Z., Ji, Y., Ma, X., Wen, J., Wei, W., & Huang, S. (2015) · International Journal of Ophthalmology · doi:10.3980/j.issn.2222-3959.2015.04.02 · Cited by 38
Sun, D., Maeno, H., Gujrati, M., Schur, R., Maeda, A., Maeda, T., Palczewski, K., & Lu, Z. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500192 · Cited by 37
Chen, H., Sun, S., Li, J., Du, W., Zhao, C., Hou, J., Xu, Y. H., & Cheng, L. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11460 · Cited by 36
Kim, K. E., Jang, I., Moon, H., Kim, K. G., Jeoung, J. W., Park, K. H., & Kim, H. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16538 · Cited by 35
Self-citationImai, H., Misra, G. P., Wu, L., Janagam, D. R., Gardner, T. W., & Lowe, T. L. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16998 · Cited by 35
Sepah, Y. J., Sadiq, M. A., Boyer, D. S., Callanan, D., Gallemore, R. P., Bennett, M., Marcus, D. M., Halperin, L. S., Hassan, M., Campochiaro, P. A., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.08.040 · Cited by 35
SUPRACHOROIDAL DRUG INFUSION FOR THE TREATMENT OF SEVERE SUBFOVEAL HARD EXUDATES
Rizzo, S., Ebert, F. G., Bartolo, E. D., Barca, F., Cresti, F., Augustin, C., & Augustin, A. (2012) · Retina · doi:10.1097/iae.0b013e3182278b0e · Cited by 32
Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules
Molokhia, S. A., Papangkorn, K., Butler, C., Higuchi, J. W., Brar, B., Ambati, B. K., Li, S. K., & Higuchi, W. I. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0081 · Cited by 31
Trypsin-mediated enzymatic degradation of type II collagen in the human vitreous.
van Deemter, M., Kuijer, R., Pas, H. H., van der Worp, R. J., Hooymans, J. M. M., & Los, L. I. (2013) · PubMed Central · Cited by 30
Kim, H. M., Ha, S., Hong, H. K., Hwang, Y., Kim, P., Yang, E., Chung, J. Y., Park, S., Park, Y. J., Park, K. H., et al. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.6.20 · Cited by 30
Self-citationAbrishami, M., Abrishami, M., Mahmoudi, A., Mosallaei, N., Roodi, M. V. A., & Malaekeh‐Nikouei, B. (2016) · Journal of Drug Delivery · doi:10.1155/2016/1368481 · Cited by 29
Chan, C. K., Abraham, P., Sarraf, D., NUTHI, A. S. D., LIN, S. G., & McCannel, C. A. (2014) · Eye · doi:10.1038/eye.2014.233 · Cited by 28
Saunders, D. J., Muether, P. S., & Fauser, S. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306771 · Cited by 27
Edelhauser, H. F., Verhoeven, R. S., Burke, B., Struble, C. B., & Patel, S. R. (2014) · Investigative Ophthalmology & Visual Science · Cited by 26
de Freitas, L. G. A., Isaac, D. L. C., Lima, E. M., de Souza, L. G., Abud, M. B., dos Reis, R. G., Tannure, W. T., & de Ávila, M. P. (2018) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.20180079 · Cited by 24
Olson, J. L., Vélez-Montoya, R., Mandava, N., & Stoldt, C. R. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9745 · Cited by 23
Papangkorn, K., Prendergast, E., Higuchi, J. W., Brar, B., & Higuchi, W. I. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0053 · Cited by 23
In VitroandIn VivoEvaluation of Carboplatin Delivery to the Eye Using Hydrogel-Iontophoresis
Eljarrat‐Binstock, E., Domb, A. J., Orucov, F., Dagan, A., Frucht‐Pery, J., & Pe’er, J. (2008) · Current Eye Research · doi:10.1080/02713680701871140 · Cited by 21
In Vivo, In VitroToxicity andIn VitroAngiogenic Inhibition of Sunitinib Malate
Dib, E., Maia, M., Filho, A. A. D. S. L., Costa, E. D. P. F., Moraes-Filho, M. N., Rodrigues, E. B., Penha, F. M., Coppini, L. P., Barros, N. M. T., Sinigaglia‐Coimbra, R., et al. (2012) · Current Eye Research · doi:10.3109/02713683.2011.635916 · Cited by 20
Kim, H. M., Park, K. H., Chung, J., & Woo, S. J. (2019) · Ophthalmic Research · doi:10.1159/000499529 · Cited by 19
Self-citationDąbkowska, M., Rogińska, D., Kłos, P., Sobuś, A., Adamczak, M., Litwińska, Z., Machalińska, A., & Machaliński, B. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s210140 · Cited by 18
Two Year SAVE Outcomes: 2.0 mg Ranibizumab for Recalcitrant Neovascular AMD
Wykoff, C. C., Brown, D. M., Croft, D. E., & Wong, T. P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.06.030 · Cited by 17
Patel, S. S., Janer, D., Miller, B., Ehrlich, J. S., Perlroth, V., & Velazquez-Martin, J. P. (2020) · Investigative Ophthalmology & Visual Science · Cited by 16
Rajpal, R., Ambatipudi, S., Azad, R. V., Sharma, Y. R., Kumar, A., Satpathy, G., & Velpandian, T. (2008) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2008.01323.x · Cited by 15
Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits
Kim, H. M., Park, Y. J., Lee, S., Son, J. Y., Hong, H. K., Ham, M. H., Jin, X., Chung, J., Park, K. H., Park, K. D., et al. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.4.7 · Cited by 13
Self-citationElhayek, R. F., Jarrett, T., Lattrell, Z., Takach, S., Jarrett, P. K., McGrath, M., Talamo, J. H., & Sawhney, A. (2017) · Investigative Ophthalmology & Visual Science · Cited by 4
Cited by
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022) · Cells · doi:10.3390/cells11213362 · Cited by 300
Hyaluronic acid in ocular drug delivery
Zhang, X., Wei, D., Xu, Y., & Zhu, Q. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118006 · Cited by 196
Considerations for Polymers Used in Ocular Drug Delivery
Allyn, M. M., Luo, R. H., Hellwarth, E. B., & Swindle-Reilly, K. E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.787644 · Cited by 159
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 173
Metadata
- Authors
- Kim, H. M., & Woo, S. J.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Woo, Se Joon
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 13
- Issue
- 1
- Pages
- 108
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC7830424
- OpenAlex
- W3118619250
- Cited by
- 198
- References
- 200
- Citations by year
- 2026: 27 · 2025: 40 · 2024: 35 · 2023: 44 · 2022: 33 · 2021: 18
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation (2020R1F1A1072795, 2018M3A9B5021319)
- National Research Foundation of Korea (2020R1F1A1072795, 2018M3A9B5021319)
- Ministry of Science and ICT, South Korea (2020R1F1A1072795)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- ocular drug delivery, retinal drug delivery, intravitreal injection, intravitreal implant, nanoparticles, hydrogels, port delivery system, anti-VEGF therapy, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular disease, subconjunctival administration, ocular bioavailability, minimally invasive drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.